| Name | Title | Contact Details |
|---|---|---|
William Blake |
Chief Technology Officer | Profile |
Cardeas BPU™ (Biosignal Processing Unit) is a biocompatible semiconductor capable of translating real-time streams of multiomics signals to digital information
As a CDMO our focus is to combine technical leadership in cell culture, microbial fermentation and viral vectors with world class cGMP manufacturing facilities to advance tomorrow`s medicines. For over 25 years our focus has been on supporting our customers with the development and manufacture of recombinant proteins, viral vaccines and gene therapies.
Siolta Therapeutics is an early stage, venture-backed biotech company focused on developing therapeutic microbial consortia to prevent and treat inflammatory diseases.
ALSP Inc. (American Life Science Pharmaceuticals, Inc.), is a privately held company based in San Diego, California, developing new small molecule drugs for treating neurodegenerative disease initially focused on traumatic brain injury and Alzheimer`s disease. Our approach is to identify key enzymes in the brain, called proteases, which produce biologically active peptides, proteins or processes that are thought to underlie the disease. We then use those enzymes as targets for screening compounds that inhibit these proteases and thereby prevent the harmful effect caused by these peptides, proteins and processes to treat the disease. By using this innovative process, our goal is to create and advance highly-effective drug development strategies and products for treating not only traumatic brain injury and Alzheimer`s disease, but other Neurodegenerative Conditions such as Huntington`s disease, Parkinson`s disease and MS, and recover quality of life for those patients and their families.
Standard BioTools Inc. (Nasdaq:LAB), previously known as Fluidigm Corporation, is driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. Learn more at www.standardbio.com or connect with us on Twitter®, Facebook®, LinkedIn, and YouTube™. Standard BioTools, the Standard BioTools logo, Fluidigm, the Fluidigm logo, “Unleashing tools to accelerate breakthroughs in human health,” Hyperion, Hyperion XTi, XTi, and X9 are trademarks and/or registered trademarks of Standard BioTools Inc. or its affiliates in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.